This paper discusses the implementation of the Joint Clinical Assessment (JCA), the implications for pharmaceutical manufacturers and biotech companies, and the impact on how they prepare for European launch. In contrast to the long-running budgetary pressures and policy shifts that affect the European market access environment, the JCA represents a more fundamental shift for European market entry and will require biopharma companies to adopt new processes and resources to address its requirements.
